ReviewZeitschrift fur Rheumatologie2025
[Anti-CD19 treatment: the new gold standard for IgG4-related diseases].
Review in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated, inflammatory, fibrosing multiorgan disease. The B cells and plasma cells play a central role in the pathophysiology, which makes B cell-targeted treatment particularly interesting for the disease. Although glucocorticoids still represent the first line treatment, recurrence under dose reduction is frequent. Immunosuppressants, such as methotrexate, azathioprine, mycophenolate mofetil or rituximab (anti-CD20) are used but larger studies on proof of benefits are lacking so that no approved treatment options for the disease currently exist. Using CD19 as the therapeutic target addresses a broad spectrum of B cell differentiation including plasmablasts. The multicenter randomized placebo-controlled phase 3 study MITIGATE (n = 135) first investigated the anti-CD19 antibody inebilizumab in active IgG4-RD. The treatment significantly reduced the risk of recurrence (10% vs. 60% under placebo), the annual exacerbation rate and the necessity for renewed administration of glucocorticoids. Additionally, under inebilizumab there was a median reduction of the IgG4 serum level of around 50% and a persisting depletion of B cells during the study period of 52 weeks. Severe undesired events occurred more frequently with inebilizumab, particularly infections and lymphopenia but without treatment-associated cases of death. Following approval of inebilizumab by the U.S. Food and Drug Administration (FDA) for IgG4-RD in 2025, approval in Europe is also soon to be expected. The anti-CD19 targeted treatment with inebilizumab could therefore become the new approved gold standard; however, long-term data on remission maintenance and health economic issues, especially in comparison to off-label treatment such as rituximab remain the subject of further research. New approaches, such as CD19 chimeric antigen receptor (CAR) T cell treatment or bispecific T cell engagers could furthermore open up future treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.